Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331251 · ClinicalTrials.gov registry record · Phase 1
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT02331251: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02331251 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 81 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02331251, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
The Phase Ib and II cohorts will enroll patients with metistatic solid tumors. Phase II only will enroll the following patients: Patients with metastatic sarcoma to be enrolled in the following 4 arms: pembro plus gemcitabine, pembro plus gemcitabine and docetaxel, pembro plus gemcitabine and vinorelbine, and pembro plus liposomal doxorubicin. Patients with metastatic pancreatic adenocarcinoma to be enrolled in the pembro plus gemcitabine and nab-paclitaxel arm. Patients with extensive-stage small cell lung cancer to be enrolled in the pembro plus irinotecan arm. Patients with ER+ breast cancer to be enrolled in the pembro and vinorelbine arm. Patients with ovarian cancer to be enrolled in the pembroplus liposomal doxorubicin arm. Patients with metastatic TNBC (ER/PR/HER2 negative) to be enrolled in the pembro plus gemcitabine arm.
Primary Outcome
Objective for phase Ib: Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with pembrolizumab (pembro) in subjects with advanced cancer.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Why NCT02331251 stopped before completion
NCT02331251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02331251 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02331251 about?
NCT02331251 is a clinical study titled "Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)". The Phase Ib and II cohorts will enroll patients with metistatic solid tumors. Phase II only will enroll the following patients: Patients with metastatic sarcoma to be enrolled in the following 4 arms: pembro plus gemcitabine, pembro plus gemcitabine and docetaxel, pembro plus gemcitabine and vino...
What is the current status of trial NCT02331251?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2014-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02331251?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT02331251?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02331251's enrollment target sits among peer trials
81 671st of 2000 higher than 1,329 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia